Category Archives: Gene therapy

Tufts R&D Outlook for 2011: Pain Mixed with Promise

By William Looney | Published: January 12, 2011
The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for [...]
Also posted in FDA, R&D, Regulatory | Tagged , , , , , , | 1 Comment

What a Week! Roche and Genentech … and Mirus!?!

By Walter Armstrong | Published: July 25, 2008
The big news this week—and, for that matter, this year—is Roche’s offer to buy the 44 percent of Genentech that it doesn’t already own. The blogosphere is burning with all the predictable predictions, dire and otherwise, attendant on a big pharma takeover of a biotech. The phrase “killing the goose that’s been laying the golden [...]
Also posted in Biotech, Deals, R&D, Strategy, Technology | Tagged , , , , , | 1 Comment

Gene Therapy Files for Approval

By Patrick Clinton | Published: July 1, 2008
An estimated one thousand clinical trials have been conducted for gene therapies in the past 20 years, but to date, not a single drug has made it to FDA approval. However, we may be a step closer as Introgen today announced that it has filed applications with FDA and EMEA for marketing approval of Advexin, [...]
Also posted in R&D | Leave a comment